Avenue Therapeutics (ATXI) Tops Q3 EPS by 34c

Avenue Therapeutics (NASDAQ: ATXI) reported Q3 EPS of $0.06, $0.34 better than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• Independent Bank receives regulatory approval for HCB Financial acquisition